Kalaris Therapeutics Inc. KLRS
2.92
(0.15)
(4.89%)
as of 25 Sep
- Market cap
- $67.1M
- P/E
- 0.0×
Follow KLRS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
12.89 | 12.23 | 12.19 | 10.98 |
Net Debt/EBITDA |
6.04 | 10.62 | 8.07 | 7.49 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 0.71 | 1.07 | 0.96 | |
Capex/Depreciation |
2.29 | 0.06 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.62) | (0.46) | (0.49) | (0.46) | |
Cash per Share |
4.12 | 7.73 | 4.10 | 3.93 | |
Shareholders Equity per Share |
2.24 | 5.16 | 2.89 | 2.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.24 | 5.16 | 2.89 | 2.42 | |
Free Cash Flow |
(11.52) | (7.07) | (11.58) | (11.05) | |
Working Capital |
72.12 | 109.10 | 90.39 | 87.18 | |
Capital Expenditures |
(0.18) | (0.02) | — | — | |
Net Current Asset Value |
38.87 | 75.89 | 57.22 | 54.05 | |
| Other line items | |||||
Quick Ratio |
12.70 | 12.15 | 12.03 | 10.70 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.61) | (0.46) | (0.49) | (0.46) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.27 | 1.42 | 1.64 | 2.40 | |
Average Assets |
101.85 | 63.95 | 106.45 | 96.19 | |
Average Common Equity |
81.49 | (8.90) | 66.22 | 55.39 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates